BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.470
+0.150 (6.47%)
At close: Jan 31, 2025, 4:00 PM
2.450
-0.020 (-0.81%)
After-hours: Jan 31, 2025, 5:27 PM EST
BioCardia Employees
As of December 31, 2023, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees decreased by 16 or -44.44% compared to the previous year.
Employees
20
Change (1Y)
-16
Growth (1Y)
-44.44%
Revenue / Employee
$3,550
Profits / Employee
-$386,100
Market Cap
11.32M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
BCDA News
- 5 days ago - BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 2 months ago - BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 5 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire
- 5 months ago - FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment - GlobeNewsWire
- 6 months ago - BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript - Seeking Alpha